Updates

Ref: Akums/Exchange/2026-27/58 November 02, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Outcome of the Board Meeting held on November 02, 2026 Respected Sir/Ma’am, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), this is to inform you that Board of Directors of Akums Drugs and Pharmaceuticals Limited (“the Company”) at its meeting held today i.e. Monday, November 02, 2026, has inter-alia considered and approved the followings: 1. Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended on September 30, 2026: The Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended on September 30, 2026, along with the Limited Review Reports thereon, as received from the Statutory Auditors, Walker Chandiok & Co. LLP, Chartered Accountants. Copies of the un-audited financial results (Standalone & Consolidated) along with the Limited Review Reports thereon are enclosed herewith as Annexure-A. Statement of Deviation or variation, pursuant to Regulation 32(1) of SEBI LODR Regulations for the quarter ended on September 30, 2026 is enclosed herewith as Annexure- B. Further, pursuant to Regulation 32(2) of SEBI LODR Regulations, the Company is not required to submit Statement of Deviation or variation from the forthcoming quarter, as hundred per cent (100%) proceeds of the Initial Public Offer has been fully utilized. 2. Mr. Sanjay Kumar, President – Operations, designated as Senior Management Personnel of the Company: On the recommendation of Nomination & Remuneration Committee, the Board of Directors has approved to designate Mr. Sanjay Kumar, President – Operations as Senior Management Personnel of the Company. Details to be provided pursuant to SEBI LODR Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure – C. The Board Meeting commenced at 02:33 P.M. (IST) and concluded at 04:23 P.M. (IST) A copy of this disclosure is being updated on the website of the Company at www.akums.in This is for your kind information and records. Thanking You Yours Faithfully For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl: As Above Annexure - A Walker Chandiok &.Co LLP Walker Chandiok & Co LLP L 41, Connaught Circus, Outer Circle, New Delhi - 110 001 India T +91 11 45002219 F +91 11 42737071 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Akums Drugs and Pharmaceuticals Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above and the consideration of the review reports of the other auditor as referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information />.NO required to be disclosed in accordance with the requirements of Regulation 33 of the Listing We,'f'. 101r<f Regulations, including the manner in which it is to be disclosed, or that it contains any material S 'b misstatement. l\J ::: ,. "\ 1l ~ /:?. . ~ ------------------------- V✓alker Chandiok & Co LLP is registered ,·,11h limited liability with identification ca,.:e"S.n.;t,,r~~ Etr-;a,""n; E.r1:.ioar.o:s,...;· Cr.ar.at-30-t C"'crr,.,;., Ci"t'r~. . ~ c::.a G;1,;;ra.11 ::L,:1,31':3:, -,:!e:atao r~;:? number AAC-2085 and has its registered io..cch, i-..c:,313 1.i:..1~~a• r:tt>-~l"1 ,~~:u -,.,j ?\.---e office at L-.11 Connaught Circus Ouier C11cle Ne·.-, Delhi 110001 India Walker Chandiok &.Co LLP Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd) 5. We draw attention to note 4 to the accompanying Statement regarding tax demand raised by the Income-tax authorities pursuant to a search and seizure operation carried out in earlier periods aggregating to { 600.92 million for the block period from 01 April 2018 to 12 March 2025. The Company had filed an appeal under section 246A of the Income-Tax Act, 2025 before the Commissioner of Income-tax (Appeals). Basis legal assessment, the management is of the view that no adjustments are required in the accompanying Statement for such demand. Our conclusion is not modified in respect of this matter. 6. We did not review the interim financial results of Akums Employee Benefit Trust ("the Trust") included in the Statement, where such interim financial results reflects total assets of { 3,007.00 million as at 30 September 2026, and total revenues of { nil and { nil, total net profit after tax of { 8.26 million and { 8.26 million, and total comprehensive income of { 8.26 million and { 8.26 million, for the quarter and six-month period ended on 30 September 2026, respectively, and net cash outflows of { 0.08 million for the six-month period ended 30 September 2026, as considered in the statement. The Statement also includes the Company's share in the net profit (including other comprehensive income) of { 8.73 million and { 19.77 million for the quarter and six-month period ended on 30 September 2026, respectively, in respect of a Limited Liability Partnership ('LLP'), whose financial result [Showing first 8,000 characters — download PDF for full document]